- Home
- BBU vs BEAM Comparison
BBU vs BEAM Comparison
Compare BBU & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBU
- BEAM
- Stock Information
- Founded
- BBU 2016
- BEAM 2017
- Country
- BBU Bermuda
- BEAM United States
- Employees
- BBU N/A
- BEAM N/A
- Industry
- BBU Engineering & Construction
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBU Consumer Discretionary
- BEAM Health Care
- Exchange
- BBU Nasdaq
- BEAM Nasdaq
- Market Cap
- BBU 2.8B
- BEAM 2.3B
- IPO Year
- BBU N/A
- BEAM 2020
- Fundamental
- Price
- BBU $33.67
- BEAM $25.14
- Analyst Decision
- BBU Buy
- BEAM Strong Buy
- Analyst Count
- BBU 6
- BEAM 12
- Target Price
- BBU $34.67
- BEAM $48.09
- AVG Volume (30 Days)
- BBU 60.5K
- BEAM 2.3M
- Earning Date
- BBU 11-06-2025
- BEAM 11-04-2025
- Dividend Yield
- BBU 0.75%
- BEAM N/A
- EPS Growth
- BBU N/A
- BEAM N/A
- EPS
- BBU N/A
- BEAM N/A
- Revenue
- BBU $27,790,000,000.00
- BEAM $55,701,000.00
- Revenue This Year
- BBU N/A
- BEAM N/A
- Revenue Next Year
- BBU $5.85
- BEAM $19.01
- P/E Ratio
- BBU N/A
- BEAM N/A
- Revenue Growth
- BBU N/A
- BEAM N/A
- 52 Week Low
- BBU $18.63
- BEAM $13.53
- 52 Week High
- BBU $36.90
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- BBU 55.90
- BEAM 58.18
- Support Level
- BBU $30.91
- BEAM $20.23
- Resistance Level
- BBU $34.39
- BEAM $22.72
- Average True Range (ATR)
- BBU 1.55
- BEAM 1.68
- MACD
- BBU 0.10
- BEAM 0.36
- Stochastic Oscillator
- BBU 85.96
- BEAM 97.41
About BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.